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ABSTRACT 
Thyroid hormones are essential for an adequate growth and development of the foetus. In 
addition to the classical association between maternal hypothyroidism and neurological 
impairment in the progeny, other adverse reproductive events have been associated with 
maternal thyroid dysfunction including infertility, miscarriage and preterm delivery. Although 
all scientific societies endorse the treatment of overt hypothyroidism; the management and/or 
treatment of subclinical hypothyroidism, hypothyroxinemia or antithyroid antibody-positive 
women should be considered with caution. Important trials have found no clear benefit of 
treatment of subclinical hypothyroidism in terms of cognitive outcomes; however, other 
interventional studies appear to reduce some of the obstetric and perinatal complications. As a 
result, the dilemma between universal screening or selective screening of women at high risk 
of thyroid dysfunction during pregnancy remains unresolved. Despite this, levothyroxine is also 
now regularly prescribed by gynaecologists and centres for reproductive medicine. In this 
context, there is increasing concern regarding the risk of over diagnosis and subsequent 
potential overtreatment. Taken together we need to reconsider how thyroid dysfunction 
should be identified in pregnant women and highlight the arguments for and against the use of 
levothyroxine in Obstetric practices. Our main findings: the mismatch between the guidelines 
recommendations and the use of LT4 in clinical settings as well as the disparity of criteria 
between scientific societies from different medical specialties. As conclusion, it is essential to 
reach agreements between both endocrinologists and obstetricians.  
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INTRODUCTION 
Over the last two decades we have witnessed a revolution in our knowledge of the role of 
thyroid hormones in intrauterine stages of development (1). However, important uncertainties 
remain regarding both the screening and management of maternal thyroid status in optimising 
perinatal outcomes (2)(3). 
Different clinical guidelines have been published by scientific societies in a relatively short 
period of time (4-7), trying to shed light into the most burning questions while two important 
trials were carried out (8, 9). However, the absence of clear evidence for the effectiveness of 
treatment of subclinical hypothyroidism on child cognition, contrasts with the promising 
results for other reproductive outcomes such as preterm delivery (10) or miscarriage (11, 12).  
But the striking paradox is that whilst the scientists search for stronger evidence, clinicians are 
increasingly using levothyroxine empirically (13, 14). 
Our aim has therefore been to summarise complementary and sometimes contradictory 
viewpoints around the assessment of thyroid function during pregnancy and the subsequent 
management of thyroid disease. 
REASONS FOR UNIVERSAL SCREENING 
Universal screening for thyroid function at early stages of gestation has become a recurrent 
controversy in the scientific literature (2, 15) and has even generated interest in the general 
population (16). In spite of the fact that scientific societies do not recommend this clinical 
approach during pregnancy at present, the most recent clinical guidelines address how to 
interpret and manage thyroid diseases that might only been identified under circumstances of 
an effective universal screening (4-7).  
In 2014, we published the arguments for universal screening (15) following the criteria 
established by Beaglehole (17): Is thyroid dysfunction during pregnancy really a health 
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problem? Do we have available simple and reliable diagnostic tests? Is universal screening 
cost-effective? Is there a simple, safe, and economically affordable treatment? And how and 
when should all of this occur?. 
This should be considered 10 key criteria for screening set out by Wilson and Junger (18).   
 
Careful analysis of these 10 criteria does in the main provide a persuasive case for universal 
thyroid screening in pregnancy.  For criteria 1 it is well established that thyroid dysfunction, 
particularly overt thyroid disease in pregnancy is an important health problem. Treatment of 
both hypothyroidism and hyperthyroidism results in improved outcomes with treatment and 
testing being both acceptable and widely available (criterias 2, 3, 5 and 6). For hypothyroidism 
in particular there is a well-recognised latent asymptomatic stage (criterias 4 and 7). The cost 
of universal thyroid screening is favourable even if only overt disease is considered (19); 
furthermore the nature of screening in pregnancy ensures it will be a continuous process 
(criteria 10). However universal thyroid screening struggles to meet criteria 8 an agreed policy 
on whom to treat. Whilst all societies would recommend treatment of overt thyroid disease, 
Box 1 Criteria for screening by Wilson and Junger. 
 
1. Is it an important health problem? 
2. Is there an accepted treatment? 
3. Are facilities for diagnosis and treatment available? 
4. Is there should a recognizable latent stage where symptoms are lacking? 
5. Is there should a suitable test or examination? 
6. Is the test acceptable to the general population? 
7. Is the natural history of the condition, including development from latent to declared 
disease understood? 
8. Is there should an agreed policy on whom to treat as patients? 
9. Is the cost of case finding (including diagnosis and treatment of patients diagnosed) 
economically appropriate? 
10. Case finding should be a continuing process and not a “once and for all” project 
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there is much greater debate as to whether subclinical hypothyroidism and isolated 
hypothyroxinemia should be treated. 
We now study these arguments in more detail. The reasons for the implementation of a 
systematic determination of thyroid hormones at the first trimester of pregnancy might also 
be classified according to the purpose of the detection itself.  
- For Endocrinology, the most obvious argument is the association of maternal overt 
hypothyroidism and obstetric and perinatal complications and the clinical impact of its 
early detection and treatment (20). Additionally, universal screening has shown to be 
more effective to detect all cases of thyroid dysfunction than targeted high-risk case 
finding approach (21,22). High risk screening will miss the majority of cases. 
- For Epidemiology, the relatively high prevalence of thyroid diseases in women 
(particularly at childbearing age) and their likelihood to be present in cases of 
infertility, recurrent miscarriages and other adverse events in obstetrical settings (23). 
- For Medical Research in general, since more and more investigation is currently 
focussed in the first “1000 days” from pregnancy until two years of life as a crucial 
stage in Epigenetics (24). In this regard, thyroid hormones play a pivotal role in 
metabolic regulation and neurodevelopment (25).  
- For Health Economics, several studies have shown that the universal analysis of 
thyroid function is cost-effective in comparison with the study of targeted groups of 
pregnant women (19,26).  
- For Public Health, because pregnancy is considered a privileged condition for 
preventive actions and a window to address some health conditions lifelong (27). 
More recently, new factors have emerged that should be regarded: 
a) The effectiveness of levothyroxine to ameliorate clinical pregnancy outcomes in 
women with subclinical hypothyroidism and/or thyroid autoimmunity undergoing 
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assisted reproduction techniques (ART) and the dissemination of these results in 
reproductive medicine journals (28) has led to the strict preconceptional 
adjustment of TSH levels in infertile women attempting conception (29). And 
levothyroxine therapy is becoming widespread among women undergoing in vitro 
fertilization even in euthyroid patients (30). 
b) The acceptance of a thyroid-stimulating hormone (TSH) level of 2.5 mU/L as the 
upper limit of normal of TSH at first trimester has resulted in a substantial increase 
in the number of women being classified as hypothyroid in different populations 
(31,32). In fact, one of the most relevant changes from the 2011 guidelines of the 
American Thyroid Association (ATA) (33) to the 2017 guidelines (7) is that in the 
absence of specific population-based reference ranges, the upper reference limit 
of 4.0 mU/L may be used instead of the previously recommended limit of 2.5 mU/L 
for TSH. However, those clinicians who have been using the former cut-off over 
the last five or six years will need time to chance their practice. 
c) Some concern has been raised that over-treatment with levothyroxine might have 
a deleterious effect on neurological development (34)  
These circumstances have created a new scenario where many pregnant women are receiving 
levothyroxine therapy in cases of mild thyroid dysfunction, or in absence of population-based 
trimester-specific reference ranges. Probably, it is time to think that a sensible approach to 
reduce the potential harmful effect of unnecessary or questionable treatments might be to 
implement responsible strategies of universal screening for thyroid diseases within the 
pregnancy surveillance programs, promoting pluridisciplinary endocrinological/obstetrical 
approaches. 
Even within those who endorse universal screening, it is not clear which test should be used 
and when to perform screening. The current guidelines recommend a single TSH test with 
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reflex TPOAb if TSH is between 2.5-10 mU/L, even though the elapsed time before the TPOAb 
determination might delay any intervention. This is particularly crucial as the first 12 weeks are 
critical for optimising neurological development. 
If a possible therapy with levothyroxine could improve pregnancy outcomes, it should be 
started as soon as possible, (or better still before conception) which reinforces the necessity to 
screen at least early in the first trimester, around 9-11 weeks of amenorrhea coinciding with 
blood test in first trimester. Furthermore, the combination of screening for thyroid dysfunction 
and aneuploidies would substantially improve the acceptability, simplicity, ease of 
administration and cost of this approach. 
 
REASONS AGAINST UNIVERSAL SCREENING 
An adequate assessment of thyroid function in pregnant women requires specific practicalities 
that cannot be underestimated (35).  
First of all, the dynamic changes in thyroid function throughout gestation (32) and its complex 
relationship with human chorionic gonadotrophin (hCG) (36) results in gestational age as a key 
determinant factor in interpreting the thyroid function tests correctly. Although the use of 
trimester-specific reference range is strongly recommended (7), they are not currently 
available in many centers or they are not based on local populations (37). Although this would 
rapidly change if universal screening was introduced.   
This dynamic change in thyroid physiology is more relevant in the early stages of gestation and, 
consequently, TSH reference limits differ widely within the first trimester of pregnancy (38). 
Whilst the lower TSH in weeks 9-12 of pregnancy are evidently explained by the high hCG 
production, considerably higher TSH values were observed earlier than 6 weeks of gestation, 
which are similar to non-pregnancy reference limits. The use of thyroid tests in ignorance of 
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gestational age can mislead their interpretation, so the same women can be classified in 
normal or pathological TSH values only depending on their gestational age at the time of 
thyroid test in first trimester (39).  
Additionally, most European countries remain mildly iodine deficient what should be taken 
into account when American guidelines are applied in Europe. The iodine intake might explain 
differences in TSH values among populations and whilst it would be ideal to only use women 
with optimal iodine intake  to establish reference ranges in pregnancy (7) this would be 
challenging to undertake in Europe in the immediate future. Women should be counselled to 
ensure adequate iodine status in pregnancy. 
The measurement of T4 concentration is also affected by the assay technology varying 
significantly by manufacturer. Assay method-specific and trimester-specific reference ranges 
should be used for serum fT4, although other alternative methods have been proposed such as 
total T4 measurement or free thyroxine index (7). 
While the standardisation of thyroid function tests remains at present as an unattainable goal 
(40), the reference ranges are highly laboratory-dependent and not applicable outside of its 
own clinical setting (37). In terms of pregnancy surveillance programmes, these factors need to 
be taken into consideration as laboratory reproducibility cannot be guaranteed. It is important 
to remark that the validity and repeatability of these tests are strongly constrained by these 
factors. 
We should also reflect on what is the purpose for the screening of thyroid function during 
pregnancy: to detect thyroid diseases and to prevent adverse outcomes (15). If the genuine 
objective of screening is to identify those women at risk for pregnancy and/or perinatal 
complications, maybe we should reinforce the search for certain subgroups of women with 
history of adverse reproductive events: previous infertility, recurrent miscarriages or preterm 
delivery. In this regard, the Practice Committee of the American Society for Reproductive 
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Medicine (ASRM) (41) include recommendations for the screening for thyroid abnormalities to 
evaluate recurrent pregnancy loss, but they do not establish an upper limit for TSH in 
pregnancy and they also found insufficient evidence to recommend routine thyroxine (T4) 
testing or screening for anti-thyroid antibodies. Additionally, the most recent preventive 
strategies for preterm delivery do not include thyroid dysfunction as a potential and 
preventable risk factor (42,43). 
Even if we would implement the systematic determination of TSH and T4 in all pregnancies, we 
would not be able to reduce the incidence of obstetric complications associated to 
autoimmune thyroid disease (AITD) (44). Although the universal antithyroid antibodies testing 
during pregnancy has been published to be cost-effective (19), its routinely implementation in 
certain clinical settings (clinics, private practice), might not be appropriate in economic neither 
or practical terms (45). 
Finally, the effectiveness of screening is also conditioned to promptly treatment of abnormal 
thyroid function tests. This would enforce the need of including the identification and 
management of thyroid dysfunction in pregnant women as competency of obstetricians and 
reproductive medicine specialists (46,47).  
In summary, before recommending a policy of universal screening of thyroid function at 
present we should address our efforts to reach substantially closer agreements in 
management between endocrine and obstetric clinics. 
IN FAVOUR OF TREATING SUBCLINICAL THYROID DYSFUNCTION 
The treatment in case of abnormal thyroid function test results ought to be a direct 
consequence of the universal screening policy. In this regard, levothyroxine therapy is 
unanimously recommended in cases of overt hypothyroidism (4-7). However, for subclinical 
hypothyroidism (SCH) or AITD the recommendations from the guidelines have been 
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experiencing frequent modifications, to try to incorporate the best evidence available over the 
last decade. 
Numerous observational studies and meta-analysis have demonstrated the association of SCH 
to adverse pregnancy and neonatal outcomes (Table 1) (48-57), but the current guidelines 
show different recommendations for SCH: for ACOG (6) there is no evidence that identification 
and treatment of subclinical hypothyroidism during pregnancy improves outcomes. The 
Endocrine Society (4) and European Thyroid Association (ETA) (5) guidelines endorse 
levothyroxine replacement independently of the presence of thyroid antibodies, although the 
recommendation level for obstetrical outcomes is weaker in women with SCH who are TPO-Ab 
negative (Table 2). The new ATA guidelines (7) recommends, firstly, the evaluation of 
thyoperoxidase antibody (TPOAb) status in pregnant women with TSH concentrations > 2,5 
mUI/l. Levothyroxine therapy is recommended for women who are positive for TPO-Abs with 
TSH greater than the pregnancy specific reference range (strong recommendation, moderate 
quality evidence) and may be considered with TSH concentrations >2,5 mUI/L and below the 
upper limit of the pregnancy specific reference range (weak recommendation, moderate 
quality evidence). 
The recent ATA guidelines have taken into account that the combination of SCH and AITD is 
more likely to be associated with poorer obstetric outcomes (58,59).  This recommendation is 
supported by the most recent findings concerning the interrelationship between SCH and 
AITD: out of all TPOAb-positive women, those with the lowest TSH suppression by hCG have 
higher risk of adverse pregnancy outcomes than those women who respond to hCG 
stimulation normally (60). 
When the interventional studies with levothyroxine performed so far are reviewed (Table 3) 
(61-76), they seem to be more effective to prevent adverse obstetric events (mainly 
miscarriage and preterm delivery) in cases where AITD was present. All these studies have 
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provided us with a more precise understanding of how to identify women at risk of pregnancy 
complications and probably will lead to better indications of therapy and consequently, more 
effective treatments. In this regard, systematic screening for TSH and TPOAb in women with a 
history of infertility or recurrent pregnancy losses need to be considered, ideally before 
conception for maximum benefit. 
For TPOAb-positive euthyroid women, the use of thyroxine might be offered individually in 
cases of assisted reproductive techniques (ART) (7), history of recurrent miscarriage (65) or 
preterm delivery (76), but there is no evidence of benefit in any other obstetric complications. 
The identification of these targeted groups of women at risk of adverse outcomes should be 
considered by reproductive medicine specialists as a priority, since thyroid dysfunction can 
jeopardize pregnancy viability and the early treatment might substantially improve the rates of 
successfully completed pregnancies (65, 76).  
Recurrent miscarriage and preterm delivery are highly prevalent entities in Obstetrics (39-41), 
which result in tremendous social and economic burdens (77, 78). At present many efforts are 
being invested in order to reduce their impact in families and health services. In this regard, 
the recent results of levothyroxine use in reducing pregnancy loss and preterm delivery are 
certainly promising (11,76). However, it is important to highlight that all the interventions with 
levothyroxine (LT4) replacement performed to date did not include any other preventive or 
therapeutic approaches: data are lacking regarding the effectiveness of LT4 in combination 
with aspirin for recurrent miscarriages or progesterone and/or pessary for preterm delivery; 
and these approaches should be evaluated through further studies. 
It might be argued that levothyroxine therapy is indicated in selected cases of mild thyroid 
hypofunction during pregnancy and its effectiveness in preventing obstetric complications 
might be greater if earlier onset, association to other drugs and dosage adjustment are 
optimized (79). 
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In summary, the indications for LT4 therapy need to be considered taking into account the 
evidence available and on a case-by-case assessment of obstetric risk factors (Table 2). 
AGAINST TREATING SUBCLINICAL THYROID DYSFUNCTION 
There are solid arguments to treat overt hypothyroidism at any stage of life and, particularly, 
during pregnancy in order to prevent serious adverse effects to the fetus (80). Nevertheless, a 
worrying percentage of levothyroxine-treated women do not receive a carefully preconception 
adjustment to optimize thyroid function before pregnancy (81) or the advice to use 
contraception until achievement of a euthyroid state before conceiving (82) or even they 
demonstrate low adherence to treatment during pregnancy (83). According to this, it would 
seem more reasonable to persevere with the optimization of treatment for overt 
hypothyroidism during the preconception stage and at early gestation than focus attention on 
subtle alterations in thyroid function tests (84). 
Furthermore, two large-scale trials were carried out to investigate the effectiveness of 
levothyroxine therapy during pregnancy to ameliorate the cognitive function in children (8, 9). 
None of these studies have shown a significant effect of LT4 on preventing adverse cognitive 
outcomes , though both studies performed a late intervention (at the end of first trimester or 
later) which might limit their effectiveness when compared with early treatment (85). Some 
interventional studies with levothyroxine offered optimistic findings (Table 3), but others have 
not found significant differences in adverse pregnancy events between treated and untreated 
groups (14, 71, 73, 75) in cases of SCH and/or AITD.  
Before considering levothyroxine therapy in cases of mild thyroid dysfunction, we should 
review how many shortcomings are present in this recommendation. First of all, we need 
reliable diagnostic criteria to identify SCH properly, specifically adjusted by gestational age and 
population-based. As we have previously indicated, the availability of own reference ranges is 
the real Achilles’ heel for a responsible screening policy in many centers. After that, a search 
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for TPO antibodies should be done, in order to determine the existence of autoimmunity, 
according to the recent ATA guidelines (7); so the onset of treatment and its potential 
effectiveness would be conditioned to the elapsed time until the complete assessment of 
thyroid function. 
In clinical settings where reference range are not available, the treatment for SCH should be 
considered with caution (TSH > 4mUI/L or TPOAb positive with TSH >2.5 mUI/L) (7). Although 
the use of thyroxine might potentially reduce miscarriage or preterm delivery rates, there is no 
evidence of effectiveness for gestational diabetes, hypertensive disorders (10) or infant 
cognitive function (8, 9). The use of levothyroxine in case of AITD with normal thyroid function 
is not currently recommended by any scientific society (4-7), although ATA guidelines consider 
the use of thyroxine in cases of TPOAb positive with TSH >2.5 mUI/L.  
However, the use a TSH cut-off of 2.5 mIU/L or 4.5 mIU/L in women who underwent in vitro 
fertilisation (FIV) (86), or intrauterine insemination (87) did not show differences in the rates of 
clinical pregnancy, delivery, or miscarriage. These results are in consonance with the 
hypothesis that the risk of adverse pregnancy outcomes is lower in women with a relatively 
normal response to hCG (60) as must occur in successful cycles in assisted reproduction. The 
empirical use of levothyroxine in women with history of infertility or before ART is not 
currently justified. 
Finally, the risk of overtreatment has become a concerning issue inherent to the overuse of 
levothyroxine in obstetric practices (88,89). Regarding the effects on the foetus of additional 
levothyroxine supply, there is no currently available fetal markers to monitor the utero-
placental passage of LT4 (90). However, samples of fetal blood obtained by cordocentesis 
showed free T4 levels concentrations higher than normal levels in around 60% of foetuses 
from euthyroid mothers with AITD who had received levothyroxine (91). Thyroid hormones 
would have a U-shaped effect on fetal development, particularly the fetal brain development 
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so as both deficiency and excess might impair fetal neurodevelopment (25). High maternal free 
LT4 concentrations have been associated to lower child IQ and lower grey matter and cortex 
volume
 
(34).  
The high free LT4 levels in maternal blood have also been associated to low birth weight and an 
increased risk for small for gestational age (SGA) newborns (92). Additionally, a recent national 
survey in USA showed that thyroid hormone treatment was associated with decreased risk of 
pregnancy loss among women with subclinical hypothyroidism, but increased risk of other 
pregnancy related adverse outcomes such as preterm delivery, gestational diabetes or pre-
eclampsia (11). All these data highlight the need of selective indications of therapy, based on 
sensible treatment threshold for women who have mildly increased TSH without other risk 
factors. 
In summary, it is highly likely that both overt hypothyroidism and the combination of 
subclinical hypothyroidism and TPOAb positivity may jeopardize pregnancy outcomes and 
which  detection and treatment with LT4 would ameliorate. Nevertheless, the need of 
treatment in cases of mild SCH with TPOAbs negative remains controversial, particularly with 
regard to cognitive outcomes. 
It is needed further scientific evidence regarding the effectiveness of LT4 therapy in euthyroid, 
TPOAbs positive women in improving fertility in cases of ART, as well as in preventing 
miscarriage and/or preterm delivery. In this regard, new randomized controlled trials with 
timely onset of treatment with LT4 are expected.  
CONCLUSION 
In order to increase the safety and effectiveness of levothyroxine treatment in Obstetric 
practices some key issues have to be addressed: the establishment of well-defined criteria for 
diagnosis adapted to every single population, laboratory and trimester of gestation; the 
acquisition of management skills in interpreting abnormal thyroid function tests by 
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Obstetricians; the inclusion of thyroid dysfunction as plausible cause for some obstetric 
complications in the algorithms in clinical decision-making, and to have more joint endocrine 
and obstetric clinics. Each of these conditions need substantial progress at present. 
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Table 1: Metaanalysis and observational studies in cases of Subclinical Hypothyroidism in pregnancy. 
 Study Results  Odd Ratio (95% CI) Comments 
Metaanalysis Zhang
48
 (2017)  
 
Miscarriage/ Pregnancy loss  1,90  (1,59-2,27)  
 
 
 
Total range for odd ratio: 
- Miscarriage: 1,90-2,01 
- Preterm delivery: 1,20-1,81 
- Growth restriction: 1,54- 3,36 
- Pre-eclampsia: 1,30-2,24 
- Gestational diabetes: 1,28-4,33 
Maraka
49
 (2016)  
 
Miscarriage/Pregnancy loss  
Preterm delivery  
Growth restriction  
Pre-eclampsia  
Gestational diabetes  
 
2,01 (1,66- 2,44) 
1,20 (0,97- 1,50) 
1,70 (0,83- 3,50) 
1,30 (1,00- 1,68) 
1,28 (0,90- 1,81) 
Tong
50
 (2016)  Growth restriction 
 
1,54 (1,06- 2,25) 
Gong
51
 (2016) 
 
 
Gestational diabetes  1,56 (1,29- 1,88) 
Toulis
52
 (2014)  
 
Gestational diabetes  1,39 (1,07- 1,79) 
Van den Boogaard
53
 
(2011)  
 
Pre-eclampsia 
Gestational diabetes 
Perinatal mortality  
 
1,70 (1,10- 2,64) 
1,40 (0,64-2,80) 
2,7 (1,60- 4,72) 
Observational 
studies 
Ying
54
 (2016)  
 
Gestational diabetes  1,81 (1,08- 1,73) TSH upper limit: 4.08 mIU/L. 
Screening before 20 weeks of gestation. 
Arbib
55
 (2016)  
 
Preterm delivery  1,81 (1,02- 3,28) TSH upper limit 2.5 mIU/L. 
Screening before 14 weeks of gestation. 
Chen
56
 (2014)  
 
Pre-eclampsia  
Growth restriction  
2,24 (1,25- 4,02) 
3,36 (1,75- 6,38) 
 
TSH upper limit 3.47, 3.81 and 4.99 
mIU/L in 1
st
, 2
nd
 and 3rd trimester, 
respectively. 
Screening at any moment during 
pregnancy. 
Karakosta
57
 (2012)  
 
Growth restriction  
Gestational diabetes 
3,10 (1.22- 8.01) 
4,33(2.10- 8.91) 
 
TSH upper limit 2.53 mIU/L. 
Screening before 15 weeks of gestation. 
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Note: Observational studies included in metaanalysis have not been reported in this table. 
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Table 2: Indications for treatment with levothyroxine during pregnancy according to the main outcomes. 
 Recommendation Pros Cons 
PREGNANCY OUTCOMES 
TPOAb Positive 
   
- TSH >10 mIU/L 
 
LT4 therapy is strongly 
recommended 
Treatment of overt hypothyroidism 
reduces the risk of pregnancy 
complications 
 
None 
- TSH 4.0-10.0 mIU/L 
 
LT4 therapy is recommended Treatment in this group reduces the risk of 
pregnancy complications and evolution to 
overt hypothyroidism 
 
LT4 therapy need to be monitored in order to avoid 
sub/overtreatment 
- TSH 2.5- 4.0 mIU/L 
 
LT4 therapy may be considered Treatment should be restricted to high 
risk of pregnancy complications such as 
infertility or recurrent pregnancy loss 
(weak evidence for preterm delivery). 
- Weak recommendation 
- High risk of overtreatment 
- No evidence of effectiveness for: 
 Gestational diabetes. 
 Hypertensive disorders 
 Growth restriction. 
 
- TSH < 2.5 mIU/L 
 
LT4 therapy is not recommended Treatment should be restricted to high 
risk of pregnancy complications such as 
infertility, ART or recurrent pregnancy loss 
and considered on a case-by-case basis  
 
There is insufficient evidence to conclusively 
determine if LT4 therapy improves fertility or 
decreases pregnancy loss risk in TPOAb positive, 
euthyroid women. 
TPOAb Negative 
 
   
- TSH >10 mIU/L 
 
LT4 therapy is strongly 
recommended 
TSH >10 mUI/L can be considered as overt 
hypothyroidism. 
 
The quality of evidence is low 
- TSH 4.0-10.0 mIU/L 
 
LT4 therapy is recommended Similar adverse risk to SCH and TPOAb 
positive when TSH exceeds 5-10 mIU/L. 
- Weak recommendation. 
- The quality of evidence is low. 
- Treatment should be considered with caution if 
reference ranges are not available. 
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 - TSH 2.5- 4.0 mIU/L 
 
LT4 therapy should not be used Low dose LT4 can be used in women 
undergoing IVF or ICSI, in order to achieve 
a TSH <2.5 mIU/L 
 
There is insufficient evidence to determine if LT4 
therapy improves fertility in TPOAb negative, 
euthyroid women. 
- TSH < 2.5 mIU/L 
 
LT4 therapy is not recommended None - Strong recommendation against the use of LT4 in 
this situation.  
- Potential risks of iatrogenic use of thyroxine in 
pregnancy: 
 Growth restriction 
 Abnormal brain morphology in children. 
COGNITIVE FUNCTION IN 
OFFSPRING 
   
- TSH >10 mIU/L 
 
LT4 therapy is strongly 
recommended 
Untreated high TSH levels have been 
associated to lower IQ scores, 
independently of the test. 
 
The effectiveness of LT4 therapy on fetal 
neurodevelopment is limited to an early intervention 
(during first trimester). 
- TSH 4.0-10.0 mIU/L 
 
LT4 therapy is recommended Early onset of LT4 treatment can improve 
cognitive function in offspring. 
The effectiveness of LT4 treatment has not yet 
conclusively demonstrated in terms of cognitive 
outcomes. 
 
- TSH 2.5- 4.0 mIU/L 
 
LT4 therapy should not be used None - High risk of overtreatment. 
- No evidence of effectiveness on cognitive 
outcomes. 
 
- TSH < 2.5 mIU/L 
 
LT4 therapy is not recommended None -   Strong recommendation against the use of LT4 in 
this situation.  
-   Potential risks of iatrogenic use of thyroxine in 
pregnancy: 
• Growth restriction 
• Abnormal brain morphology in children. 
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Table 3:  Interventional studies with levothyroxine in Subclinical Hypothyroidism and/or thyroid autoimmunity during pregnancy. 
 Study design Intervention Results Comments 
 
Vissenberg et al 
(2012)
61 
Meta-analysis Included Abalovich et al (2002)
62
 and 
Negro et al (2010)
58
 for SCH. 
 
Five studies reported on the effect of LT4 
therapy for AITD. 
 
SCH:     Miscarriage  
             Preterm delivery 
 
TAI: Miscarriage (not significant)  
           Preterm delivery. 
 
Conclusion: For SCH and AITD, 
evidence is insufficient  to 
recommend treatment with 
thyroxine. 
Yan et al 
(2012)
14 
Prospective 
Non-randomised 
53 pregnancies from 34 patients TPO Ab 
(+) with recurrent miscarriage:  
-17 pregnancies with LT4 treatment. 
-36 pregnancies without treatment. 
 
NO significant difference in the 
outcome between groups in live 
birth rate. 
Empirical thyroxine therapy in 
TPOAb(+) pregnant women did 
not seem to improve outcome.  
Lepoutre et al 
(2012)
63 
Retrospective 96 TPO Ab (+) pregnant women 
-49 treated with LT4. 
-47 no treated. 
 
     Miscarriage rate Potential benefit of universal 
screening and LT4 treatment in 
pregnant women with TAI. 
Reid et al 
(2013)
10 
Meta-analysis For SCH included Rotondi et al (2004)
64
, 
Negro et al (2006)
65
, Negro et al (2007)
66
 
and Yassa (2010)
67
. 
 
    Preterm delivery. 
 
No effect on Pre-eclampsia. 
There was a trend towards 
reduced risk of miscarriage with 
LT4, but did not reach statistical 
significance. 
 
Velkeniers et al 
(2013)
28 
Meta-analysis Women with SCH undergoing ART. 
Included Negro et al (2005)
68
, Abdel 
Rahman et al (2010)
69
 and Kim et al 
(2011)
70
. 
 
   Delivery rate. 
 
    Miscarriage rate. 
In an ART setting, no data are 
available on the effects of LT4 
treatment on preterm delivery or 
pre-eclampsia. 
Bernardi et al 
(2013)
71 
Prospective 
Non-randomised 
Women with SCH and history of recurrent 
early pregnancy loss 
NO significant difference in the 
outcome between groups in live 
The prevalence of SCH in this 
recurrent early pregnancy loss 
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-24 treated with LT4. 
- 15 no treated. 
 
birth rate. (REPL) cohort was 19%. 
 
Bartáková et al 
(2013)
72 
Prospective 
Non-randomised 
Cost-effectiveness analysis of screening 
and treatment after spontaneous 
abortion (SpA) 
-73 SCH and/or TAI treated with LT4. 
38 SCH and/or TAI untreated. 
 
    Successfully completed 
subsequent pregnancies. 
Screening for thyroid disorders in 
women after SpA and treatment 
with LT4 is cost-saving and it 
improves the subsequent 
pregnancy rate. 
Lata et al 
(2013)
73 
Prospective 
Non-randomised 
Women with 2 or more consecutive 
miscarriages. 
-31 with AITD and 27 with SCH were 
treated with LT4. 
 
Compared to 100 healthy women without 
a history of miscarriage. 
 
Following LT4 treatment, NO 
difference in miscarriage rate 
between hypothyroid and 
euthyroid individuals in TPO Ab 
(+) women.  
The prevalence of AITD was 
higher in pregnant women with a 
history of recurrent miscarriage 
compared with healthy pregnant 
control population. 
 
Ma et al 
(2015)
12 
Prospective 
Non-randomised 
Screening group (675 pregnancies) was 
compared to control group (996 
pregnancies). 
105 SCH from screening group were 
treated with LT4. 
252 SCH from control group did not 
receive treatment.  
 
    Miscarriage rate. 
 
    Fetal macrosomia risk. 
 
    Cesarean risk. 
Screening and intervention of 
SCH can reduce the risk of 
miscarriage. 
 
No significant differences were 
observed in other pregnancy 
outcomes between the two 
groups. 
 
Maraka et al 
(2016)
74 
Retrospective 
 
 
82 women with SCH were treated. 
284 women with SCH did not received 
treatment with LT4. 
 
    Risk of low birth weight. 
 
    Risk of low Apgar score. 
Other pregnancy-related adverse 
outcomes were similar between 
the two groups.  
Negro et al  Prospective 198 euthyroid, AITD (+) treated with LT4. NO significant difference in Levothyroxine intervention had 
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(2016)
75 
Randomised 195 euthyroid, AITD (+) untreated. 
197 euthyroid, AITD (-) untreated. 
miscarriage or preterm delivery 
rate between the 3 groups. 
 
no impact on the rate of 
miscarriage or preterm delivery 
in euthyroid TAI (+) women. 
 
Nazarpour et al 
(2016)
76 
Prospective 
Randomised 
65 TPO Ab (+) women treated with LT4. 
66 TPO Ab (+) women untreated. 
131 TPO Ab (-) women untreated. 
   Preterm delivery rate. The number needed to treat 
(NNT) for preterm birth was 1.7  
 
Maraka et al 
(2017)
11 
Retrospective 843 women with HSC were treated. 
4562 women with SCH did not received 
treatment with LT4. 
  Pregnancy loss. 
    
  Preterm delivery. 
  Gestational diabetes. 
  Pre-eclampsia. 
The adjusted odd of pregnancy 
loss were lower in treated 
women than in untreated 
women if their pre-treatment 
TSH concentration was 4.1-10 
mIU/L. 
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